Stem Cell Biological Potency Testing: Assay Principles, Methods, and Quality Standards

Stem cell biological potency testing is the analytical foundation for demonstrating that cell therapy products possess the biological activity required to achieve their intended therapeutic effect. This article provides a comprehensive technical overview of potency assay design, sample types, testing items, validated analytical methods, and regulatory expectations aligned with ICH, ISO, USP, and pharmacopoeial standards. Whether you develop mesenchymal stromal cell therapies, pluripotent stem cell derivatives, or hematopoietic products, understanding potency testing is essential for lot release, process comparability, and regulatory submission success.

Technical Overview

Biological potency is defined as the quantitative measure of a biological activity that is linked to the intended clinical effect of a stem cell product. Potency is distinct from identity (what the cells are), purity (what contaminants are absent), and viability (how many cells are alive). Regulators worldwide, including those applying ICH Q6B specifications for biological products, USP general chapters for cell and gene therapy products, and ISO 13022 for risk management of medical products containing viable human cells, expect a scientifically justified potency assay or assay matrix as part of the control strategy for any investigational or licensed stem cell therapeutic.

A robust potency testing strategy typically combines a quantitative functional assay with orthogonal supporting measurements such as surface marker expression, secreted factor profiling, and gene expression signatures. Potency assays must be validated or qualified for specificity, accuracy, precision, linearity, range, and robustness in accordance with ICH Q2(R2), and they should be stability-indicating so that changes during storage, shipment, or manufacturing can be detected. Accredited third-party laboratories operating under ISO/IEC 17025 or ISO 15189 quality systems, with cleanroom and cell culture infrastructure compliant with ISO 14644, are frequently engaged to perform these studies under GMP-compatible conditions.

Testing Samples

Mesenchymal Stromal Cells (MSCs)

Samples derived from bone marrow, adipose tissue, umbilical cord, Wharton's jelly, and placenta, submitted as fresh or cryopreserved cell suspensions, harvested drug substance, or final drug product. MSC potency testing is the largest application area, driven by the immunomodulatory and regenerative mechanisms attributed to these cells.

Hematopoietic Stem and Progenitor Cells (HSCs)

Umbilical cord blood units, bone marrow aspirates, and mobilized peripheral blood apheresis products, as well as enriched CD34-positive cell populations. Potency testing for these products centers on clonogenic progenitor function and engraftment-related activity.

Pluripotent Stem Cells and Derivatives

Human embryonic stem cell lines, induced pluripotent stem cell (iPSC) lines, clonal sublines, and differentiated derivatives such as neural progenitors, cardiomyocytes, retinal pigment epithelial cells, and beta-like islet cells. Testing addresses pluripotency status, lineage commitment, and functional maturity of the differentiated population.

Cell Banks and Intermediate Products

Master cell banks, working cell banks, end-of-production cells, and in-process intermediates collected at defined manufacturing steps. Potency data from these samples support bank qualification, process characterization, and comparability exercises.

Cell-Derived Products

Conditioned media, lysates, and extracellular vesicle preparations, where potency is evaluated through the quantified biological activity of secreted factors rather than viable cell function.

Testing Items

Depending on the product type, mechanism of action, and stage of development, a stem cell biological potency testing panel may include the following items:

• Cell viability and membrane integrity (dye exclusion, flow cytometric viability dyes)
• Cell counting and concentration determination in accordance with ISO 20391-1 and ISO 20391-2
• Immunophenotypic identity by multiparameter flow cytometry, including positive markers (for example CD73, CD90, CD105 for MSCs) and negative markers (CD34, CD45, CD14 or CD11b, CD19 or CD79a, HLA-DR)
• Clonogenic capacity, including colony-forming unit fibroblast (CFU-F) assays for MSCs and hematopoietic colony assays such as CFU-GM and BFU-E for HSC products
• Tri-lineage differentiation potential: osteogenic, adipogenic, and chondrogenic induction with lineage-specific staining and gene expression confirmation
• Immunomodulatory function, such as T-cell proliferation suppression, indoleamine 2,3-dioxygenase (IDO) activity, PGE2 secretion, and macrophage polarization assays
• Secreted factor quantification, including VEGF, HGF, IL-6, TGF-beta, TSG-6, and angiogenic cytokines
• Angiogenic and trophic activity, including endothelial tube formation, scratch wound closure, and transwell migration assays
• Proliferation capacity and senescence status, including population doubling time, Ki-67 expression, senescence-associated beta-galactosidase, and p16 or p21 expression
• Pluripotency assessment for PSCs, including OCT4, SOX2, NANOG, TRA-1-60, and alkaline phosphatase, with embryoid body or directed differentiation confirmation
• Genetic stability characterization, including karyotyping, FISH, SNP arrays, and STR-based identity confirmation
• Companion safety testing such as sterility, mycoplasma, and bacterial endotoxin, performed alongside potency release panels

Testing Methods

Flow Cytometric Immunophenotyping

Multiparameter flow cytometry is the primary method for identity and purity assessment. Assays are designed with validated antibody clones, fluorescence-minus-one controls, and gating strategies that satisfy predefined acceptance criteria. For MSC products, the consensus positive and negative marker panel defined by the International Society for Cellular Therapy is widely applied as the identity backbone, while potency-related markers such as PD-L1, CD54, or CD274 can be incorporated as functional surrogates.

Colony-Forming Unit Assays

Clonogenic assays remain the classical functional potency readout. CFU-F assays measure the frequency of proliferative fibroblast progenitors in MSC populations, while semi-solid hematopoietic cultures quantify CFU-GM, BFU-E, and CFU-GEMM colonies for cord blood and transplant products. Colonies are scored microscopically by trained analysts under standardized incubation conditions, with reference controls run in parallel.

Directed Differentiation Assays

MSC multipotency is demonstrated by inducing osteogenic, adipogenic, and chondrogenic lineages in vitro and confirming differentiation through Alizarin Red S, Oil Red O, and Alcian Blue or Safranin O staining, supported by quantitative alkaline phosphatase activity and lineage gene expression (RUNX2, PPAR-gamma, SOX9, ACAN). Differentiated PSC derivatives are characterized by immunocytochemistry, flow cytometry, and functional markers appropriate to the target lineage.

Immunomodulatory Function Assays

Because the therapeutic mechanism of many MSC products is immunomodulation, cell-based functional assays are central to potency. Common designs include co-culture suppression of anti-CD3 and anti-CD28 stimulated T-cell proliferation measured by CFSE dilution, IFN-gamma-primed IDO activity quantified by kynurenine spectrophotometry, IL-6 and PGE2 secretion measured by immunoassay, and monocyte-to-M2 macrophage polarization assays. Results are expressed relative to a qualified reference cell lot, generating a relative potency value.

Secretome and Cytokine Profiling

ELISA and multiplex bead-based immunoassays quantify secreted bioactive factors in conditioned media. Concentration-response curves for key factors such as VEGF, HGF, and TSG-6 can be established as quantitative potency endpoints, provided the selected factor is mechanistically linked to the intended effect and shown to be stability-indicating.

Functional Bioassays for Angiogenesis, Migration, and Wound Repair

Endothelial tube formation on extracellular matrix, scratch wound closure kinetics, and transwell chemotaxis assays provide orthogonal functional readouts for products claiming trophic or regenerative mechanisms. These assays are typically performed with automated imaging and image analysis to reduce operator bias and improve precision.

Molecular Potency Assays

Quantitative RT-PCR and digital PCR enable potency gene expression signatures, offering high precision and short turnaround. Emerging approaches use targeted transcriptomic panels and computational models to produce a composite potency score, which must be analytically validated and clinically justified before use in lot release.

Method Validation and Data Management

All quantitative potency methods used for release or stability decisions are validated per ICH Q2(R2), covering specificity, linearity, range, accuracy, repeatability, intermediate precision, and robustness. Parallel-line or sigmoidal dose-response models with relative potency calculations are applied against qualified reference standards. Control charts trend assay performance and product behavior over time, supporting ongoing process control and comparability conclusions after manufacturing changes.

Applications

Stem cell biological potency testing supports the full product lifecycle across regenerative medicine development and manufacturing:

• Lot release testing of clinical and commercial cell therapy products against predefined potency specifications
• Potency assay development, qualification, and validation for IND and IMPD submissions and marketing authorization dossiers
• Comparability studies following manufacturing, site, or formulation changes
• Cell bank qualification and characterization of master and working cell banks
• Cryopreservation and shelf-life stability programs, including transport simulation studies
• Donor and raw material qualification, including ancillary materials evaluated per USP guidance
• Release and stability testing of cell-derived conditioned media and extracellular vesicle products
• Preclinical research support and mechanism-of-action studies for academic and industrial programs

FAQ

What is the difference between potency and viability?

Viability measures the proportion of cells with intact membranes and metabolic activity, while potency measures the strength of a biological activity linked to the intended therapeutic effect. A product can show high viability yet low potency, which is precisely why regulators require a functional potency assay rather than viability alone for lot release.

How many potency assays are required for a stem cell product?

There is no single mandated assay. Most approved and investigational products use a matrix approach combining one quantitative functional assay with orthogonal surrogate markers, because a single assay rarely captures all relevant biological activities. The matrix must be justified by the product mechanism of action and clinical indication.

Which potency assays are most common for MSC products?

Frequently used assays include T-cell suppression co-culture, IDO activity or kynurenine production, PGE2 and IL-6 secretion, CFU-F clonogenicity, and tri-lineage differentiation. The optimal choice depends on the clinical indication, since an immunomodulatory indication and a wound-healing indication will emphasize different mechanisms.

How are potency assay acceptance criteria established?

Acceptance criteria are derived from manufacturing experience, clinical experience where available, and assay variability. Sponsors typically analyze multiple historical lots, link results to relevant bioactivity, and set specifications that the manufacturing process can reliably meet while excluding non-functional lots.

How much sample is required for potency testing?

Requirements vary by method. Flow cytometry may need only a few hundred thousand cells, while functional co-culture and differentiation assays can require several million cells. Testing plans should account for replicate wells, reference controls, and reserve volumes, particularly for limited products such as cord blood units.

What is the typical turnaround time for potency testing?

Immunophenotyping and viability results are often available within one to three days. CFU assays require approximately two weeks of culture before scoring, and differentiation assays may take three to four weeks from induction to final staining and gene expression analysis.

Can potency testing be outsourced?

Yes. Many sponsors transfer validated potency methods to accredited third-party laboratories operating under ISO/IEC 17025 or GMP-aligned quality systems for routine release testing, while retaining assay ownership, reference standards, and comparability data internally.

Do potency assays need to be stability-indicating?

Yes. Regulatory expectations treat potency as a critical quality attribute, so the assay must be capable of detecting degradation of biological activity during storage, freeze-thaw handling, and transport, which is why functional assays are strongly preferred over purely descriptive markers for shelf-life assignment.